ArticleCureus2026
Hereditary Bilateral Retinoblastoma Detected on Screening in a Two-Month-Old Infant With a Strong Family History.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma is the most common primary intraocular malignancy of childhood and may occur sporadically or as a heritable disease related to pathogenic variants in RB1. Early ophthalmic screening of at-risk infants can identify tumors at a stage amenable to globe-sparing therapy. We report a two-month-old asymptomatic female infant with a strong maternal family history of retinoblastoma who was found on screening to have a Group B lesion in the right eye and three Group A lesions in the left eye, according to the International Classification of Retinoblastoma. Following multidisciplinary evaluation, she underwent focal therapy with cryotherapy to the left eye and argon laser photocoagulation to the right eye, together with four 21-day cycles of systemic carboplatin, etoposide, and vincristine. Treatment was well tolerated with minimal reported adverse effects. This case highlights the importance of family history, early screening, and multidisciplinary care in children with suspected heritable retinoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.